结直肠癌肝转移的分子和免疫组化标志物及其预后和预测意义。

Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20122 Milan, Italy.

Department of Biomedical, Surgical and Dental Sciences, University of Milan, via Francesco Sforza 35, 20122 Milan, Italy.

Int J Mol Sci. 2018 Oct 3;19(10):3014. doi: 10.3390/ijms19103014.

Despite the significant recent achievements in the diagnosis and treatment of colorectal cancer (CRC), the prognosis of these patients has currently plateaued. During the past few years, the opportunity to consider multiple treatment modalities (including surgery and other locoregional treatments, systemic therapy, and targeted therapy) led to the research of novel prognostic and predictive biomarkers in CRC liver metastases (CRCLM) patients. In this review, we seek to describe the current state of knowledge of CRCLM biomarkers and to outline impending clinical perspectives, in particular focusing on the cutting-edge tools available for their characterization.

尽管近年来在结直肠癌（CRC）的诊断和治疗方面取得了重大进展，但这些患者的预后目前已趋于稳定。在过去的几年中，考虑多种治疗方式（包括手术和其他局部区域治疗、全身治疗和靶向治疗）的机会促使人们对结直肠癌肝转移（CRCLM）患者的新型预后和预测生物标志物进行了研究。在这篇综述中，我们旨在描述 CRCLM 生物标志物的现有知识状况，并概述即将出现的临床前景，特别是侧重于用于其特征描述的前沿工具。